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Abstract
Background: Argininosuccinic aciduria (ASAuria) is an autosomal recessive disorder of the urea cycle relatively
common in Saudi Arabia as a consequence of extensive consanguinity. It is the most common urea cycle disorder
identified in the Saudi population, which therefore prioritizes the need to delineate the underlying molecular
defects leading to disease.
Findings: We utilized Whole Genome Amplification (WGA), PCR and direct sequencing to identify mutations
underlying ASAuria cases diagnosed by our institution. A missense mutation that accounts for 50% of Saudi
ASAuria patients was recently reported by our laboratory. In this study we report a further six novel mutations (and
one previously reported) found in Saudi patients with ASAuria. The novel four missense, one nonsense and one
splice-site mutation were confirmed by their absence in >300 chromosomes from the normal population.
Pathogenicity of the novel splice-site mutation was also confirmed using reverse transcriptase-PCR analysis. Cross
species amino acid conservation at the substituted residues described were observed in some but not all instances.
Conclusions: Together, the eight mutations described by our laboratory, encompass >90% of ASAuria patients in
Saudi Arabia and add to about 45 other ASAuria mutations reported worldwide.
Introduction
Argininosuccinic aciduria (ASAuria; OMIM 207900) or
argininosuccinate lyase (ASL; EC 4.3.2.1) deficiency is an
autosomal recessive inborn error of the urea cycle. ASL
catalyses the reversible cleavage of argininosuccinic acid
(ASA) into arginine and fumarate. ASL is a homotetra-
mer of 50-kDa subunits and is found in the cytosol of
hepatoctyes, renal cells and fibroblasts. Neonatal presen-
tation of ASAuria is most common and is characterized
by lethargy, vomiting, hypothermia, decreased con-
sciousness and coma usually occurring between 24 and
72 hrs. Biochemical analysis reveals hyperammonemia,
elevated plasma citrulline levels and increased ASA in
dried blood spots (DBS), plasma and urine[1].
The ASL gene is located on chromosome 7q11.2, and
is approximately 35 kb in length and spans 17 exons (16
coding). Mutations in ASL have been shown to cause
ASAuria but due to substantial clinical and genetic het-
erogeneity reported in this disease, a clear genotype/
phenotype correlation has not been clearly defined
[2-10]. Recently, an ASL pseudogene was reported to be
located in the centromeric region of chromosome 7
[11].
ASAuria is the most common inborn error of the urea
cycle in Saudi Arabia, a consequence of extensive con-
sanguinity. It is diagnosed clinically and confirmed bio-
chemically by the elevated levels of ASA and citrulline
in dried blood spots (DBS), using tandem mass spectro-
metry (MS/MS) [12]. Recently, our laboratory reported
that a novel missense mutation, Q354X (c.1060C>T),
was found to be exclusively homoallelic in 50% of ASA
patients that were screened [13]. In this paper, we report
the identification of a further six novel mutations, that
in combination with a previously reported mutation and
Q354X provide above 90% coverage of the mutations
underlying ASA in Saudi Arabia.
Materials and methods
Patients
All but one of the patients being reported here were
diagnosed by our newborn screening laboratory based
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DBS. The samples were referred to the laboratory from
sick neonates where a diagnosis of urea cycle disorder
was suspected. No additional clinical details are available
on these patients. Waiver of informed consent was pro-
vided by the Institutional Review Board (IRB) of the
King Faisal Specialist Hospital and Research Centre
(KFSH&RC), on the basis of anonymization of all study
samples. The whole blood of one clinically diagnosed
affected individual (and her parents) was also screened
as part of this study via the molecular genetic testing
services provided by the Saudi Diagnostics Laboratory
for KFSH&RC. As these samples were submitted for
routine diagnostic purposes in the same hospital, the
IRB in place, covering these samples remains applicable.
Sample collection and DNA extraction
Genomic DNA was extracted from whole blood by stan-
dard salt-precipitation methods. DNA was prepared
from DBS previously used for MS/MS analysis. Briefly, a
sample 2 mm in diameter was punched out from each
spot and placed in a 96-well plate. The 2 mm discs were
re-hydrated with 10 μl of phosphate-buffered saline
(PBS) at room temperature prior to DNA extraction and
amplification. Extraction and amplification were carried
out as described for the REPLI-g TM kit (Molecular Sta-
ging Inc., New Haven, CT, USA) with minor modifica-
tions. Extractions were assembled on ice by adding 10
μl of cell lysis solution (400 mM KOH, 10 mM EDTA
at pH 8.0, and 50 mM dithiothreitol), mixed briefly with
the PBS-soaked discs and incubated for 10 min. Then
10 μl of neutralization solution (800 mM Tris-hydro-
chloride) was added and mixed gently by pipetting. This
lysate mixture (2 μl) was then used as template per 10
μl of whole genome amplification (WGA) reaction.
WGA
WGA [14] was performed in a total volume of 10 μl.
Amplification reactions were assembled in 96-well plates
by mixing 2.5 μl4 ×b u f f e r ,5 . 4μld d H 2O, 0.1 μlø 2 9
DNA polymerase, and 2 μl of the lysate mixture. Reac-
tions were incubated at 30°C for 16 h and terminated by
heating to 65°C for 3 min. The amplification reactions
were diluted 50 fold in ddH2O (DNA concentration ~10
ng/μl) and dilutions used in PCR amplification and
direct sequencing.
Mutation Detection
For sequence analysis of blood spot samples, WGA gen-
erated DNA was amplified by PCR using intronic pri-
mers designed to amplify the 16 coding exons of the
ASL gene (primer sequences and conditions are available
on request). PCR was performed in a final volume of 20
μl containing approximately 10 ng of genomic DNA, 50
mM KCl, 10 mM Tris-HCl (pH 8.3), 1.5 mM MgCl2,
100 μM deoxyribonucleotide triphosphates (dNTPs), 1
unit of Qiagen (Valencia CA, USA) HotStar Taq poly-
merase, and 50 ng of each primer. Thermocycling
(Applied Biosystems Inc, Foster City, CA, USA) con-
sisted of an initial denaturation at 95°C for 15 min fol-
lowed by 35 cycles of PCR. Each cycle of PCR consisted
of denaturation at 94°C for 60 s, annealing at 62-68°C
for 60 s and extension at 72°C for 60 s. A final exten-
sion step of 10 min at 72°C was added. Sequencing reac-
tions were performed using an ABI Prism Big Dye
Terminator v3.1 Cycle Sequencing Kit following the
manufacturer’s instructions and were processed on a
MegaBACE 1000 DNA Analysis System (Molecular
Dynamics; Sunnyvale, CA, USA). Sequence analysis was
performed using the SeqMan 6.1 module of the Laser-
gene (DNA Star Inc. WI, USA) software package, then
compared to the reference GenBank sequence (accession
no. AF376770). Numbering commenced with the A of
the ATG initiation codon as +1.
RT-PCR
To determine the effect of the novel splice-donor site
mutation detected in intron 13 with respect to mRNA
splicing, a fragment comprising exon 12, 13 and 14 of
ASL was amplified using RT-PCR with mRNA isolated
from peripheral blood lymphocytes. One microgram of
total RNA from the patient and a normal control was
reverse transcribed using an aliquot of a reverse tran-
scription reaction containing 1 × PCR buffer, 2.5 mM
MgCl2, 0.2 mM of each dNTP, and 0.5 U AMV reverse
transcriptase (Roche Diagnostics GmbH, Mannheim,
Germany). 10 μl of cDNA was amplified by PCR using
the 5’ primer (GGC TCC TGA TGA CCC TCA A) and
the 3’ primer (ATA GGC AAG GTC AGT GGC CAG).
Thermocycling consisted of an initial denaturation at
94°C for 10 min followed by 35 cycles of PCR at 94°C
for 60 s, 64°C for 60 s and extension at 72°C for 60 s.
URLs
We used the Ensembl website http://www.ensembl.org
to obtain exon and intron boundaries and the reference
GenBank cDNA sequence, and Primer3 http://frodo.wi.
mit.edu/primer3/ to design appropriate primers.
Results
Twenty-nine patients were studied, 15 (54%) were
homoallelic for the previously reported Q354X muta-
tion. Direct sequencing of ASL gene in the remaining 13
patients revealed the presence of seven mutations (4
missense, 2 nonsense and 1 splice-site). The next most
common mutation was a novel transition c.556C>T in
exon 7 and resulted in the substitution of arginine for
tryptophan (R186W). Eight patients (29%) were
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be a compound heterozygote having R186W in combi-
nation with a transversion, c.343G>T in exon 4 which
resulted in the novel substitution of aspartic acid for tyr-
osine at position 115 in the amino acid sequence
(D115Y). A homozygous transition c.469G>A in exon 6
was found in one patient and resulted in the previously
unreported substitution of glycine for arginine at posi-
tion 157 (G157R). The fourth novel missense mutation,
P166S, observed in one patient was caused by a homo-
zygous transition c.496C>T in exon 6.
From our patient group, there was a single affected
individual whose whole blood was submitted to our
laboratory for molecular genetic diagnostic testing. By
direct sequencing, the patient was shown to be homozy-
gous for a novel intronic splice-donor site mutation
l o c a t e di ni n t r o n1 3o fASL (IVS13+5G>C). In addition,
the parents of this patient were shown to be heterozy-
gous carriers for this mutation, confirming segregation
of the mutation in an autosomal recessive pattern of
inheritance. However, to confirm that this splice-site
mutation in intron 13 alters splicing, a cDNA fragment
was amplified and directly sequenced in the index
patient and an unrelated control sample that encom-
p a s s e dap a r to fe x o n1 2t op a r to fe x o n1 4 .Ab a n do f
222 bp was detected in the normal control sample
whereas subsequent mRNA analysis of the patient
revealed a band of 138 bp. The predicted normal size of
exon 13 is 83 bp and this exact difference in size
between the normal control and patient fragments is
highly indicative that exon 13 is completely spliced-out
in the patient and hence confirms that this mutation
does affect normal splicing.
One patient was homozygous for a c. 544 C>T transi-
tion, which resulted in the previously reported nonsense
mutation R182X [11], in exon 7 of ASL, predicting pre-
mature truncation of the normal 460 amino acid ASL
product at position 182.
Finally, one patient was homozygous for a transver-
sion, c.1081G>T, also resulting in a novel nonsense
mutation, G361X which also predicts premature trunca-
tion of the normal amino acid ASL product. The one
novel nonsense and four missense mutations were con-
firmed by their absence in ~300 chromosomes from the
normal population. The presence of these mutations
was confirmed in parental DNA when available.
To further investigate the five novel ASL coding var-
iants, multiple sequence alignment (protein) was per-
formed using the ClustalW program (GenomeNet) to
determine cross-species conservation of ASL at the posi-
tion of each novel mutation (Figure 1). Strong cross-spe-
cies conservation of ASL was observed at the sites in all
4 of the novel missense mutations. However, amino acid
variation was noted at residues (R182X, Q354X and
G361X) where nonsense mutation resulted in premature
truncation.
Figure 1 Consensus sequences of the ASL gene superfamily. The alignment shading corresponds to consensus of 100% (black) and 80%
(dark gray). (A) corresponds to amino acid conserved domain I containing the novel mutations D115Y, G157R and P166S. (B) corresponds to
amino acid conserved domain II containing the nonsense mutations R182X, and R186W. (C) corresponds to amino acid conserved domain III. (D)
corresponds to the carboxy terminal containing Q354X and the novel G361X mutations. The ‘↓’ represents the position of the mutation. The ‘*’
represents the putative catalytic residues. FUM, fumarase; ASP, ammonia-aspartate lyase; ADL, adenylosuccinate lyase; CMLE, 3-carboxy-cis, cis-
muconate lactonizing enzyme; D2C, δ2 crystallin; D1C, δ2 crystallin; ASL, argininosuccinate lyase. The alignment was performed using the
ClustalW program (GenomeNet).
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Although approximately 50 mutations underlying ASA
have been reported to date, apparently only three have
been identified in Arab patients, one being the result of
a previous study by our group[8,15]. In this study with
the exception of one patient, a compound heterozygote
for the R186W and D115Y mutations, all patients had
homoallelic mutations reflecting consanguinity in the
Saudi population. Four of the novel mutations identified
by this study occur in highly conserved domains of ASL
and indeed other members of the ASL superfamily such
as class II fumarase [16], adenylosuccinate lyase [17],
L-aspartase [16,18], 3-carboxy-cis, cis-muconate lacto-
nizing enzyme (CMLE) [19], and δ crystalline [20,21]
(Figure 1). Whilst overall amino acid sequence similarity
of these enzymes is low (<20%), three regions of highly
conserved residues across the ASL superfamily represent
consensus sequences which are involved in the catalytic
mechanism of these enzymes [22]. The crystal structure
of ASL like five members of the ASL superfamily
includes a common protein fold where monomers con-
taining three structural domains form dimers which
associate to form a tetramer [23]. The superfamily con-
sensus sequences are spatially removed from each other
in the monomers, but come together at each of the four
corners of the tetramer to form four active site clefts.
Mutations within the superfamily consensus sequences
are highly likely to alter active site clefts to the detri-
ment of enzymatic activity and offer explanation for the
highly conserved nature of these regions. The R186W
mutation which results in the substitution of arginine by
tryptophan occurs 3 residues upstream of the putative
catalytic residue of the central ASL superfamily consen-
sus domain and predicts pathogenicity of this change
consistent with its rare occurrence in the general popu-
lation. A second novel mutation D115Y, identified by
this study occurs in the amino ASL superfamily consen-
sus domain once again consistent with pathogenicity
related to alteration of the active cleft. A third missense
mutation G157R occurs between the amino and central
consensus domains with no immediately apparent func-
tional significance. However, this alteration was not
observed in ~300 chromosomes from the ethnically
matched normal population. Three nonsense mutations
were identified among Saudi ASAuria patients, two from
this study (R182X and G361X), the other having being
previously reported [15].
The homotetrameric structure of ASL introduces the
possibility of clinical heterogeneity resulting from inter-
allelic complementation. However, given extensive con-
sanguinity in the Saudi population and as evidenced by
this study, homoallelic mutations are almost universally
observed in this group negating clinical heterogeneity
resulting from interallelic complementation. Only one
compound heterozygote was identified in this study and
had mutations in the amino and central ASL superfam-
ily consensus domains. The clinical consequence of this
and the role of complementation could not be assessed
since all patient samples were fully anonymized as part
of IRB approval.
Together the eight mutations described in this and our
previous study, cover above 90% of the underlying muta-
tions of ASL in ASAuria patients of Saudi ethnicity. The
two most common (Q354X and R186W) cover 89% of
the population with others likely to represent private
familial mutations. This coverage provides an efficient
molecular diagnosis of ASAuria in the Saudi population
and lays the foundation for preventative measures includ-
ing inductive screening of extended families, counseling,
and regional pre-marital screening. In addition, identifica-
tion of these mutations enables provision of pre-implan-
tation and prenatal diagnosis as appropriate. As a result
of this and a previous study [15], substantial reduction in
live births with ASAuria in the Saudi population is possi-
ble. The common mutation identified by this study may
also be more widely relevant in the Arab world.
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